KAREN FRESHWATER: Open Payments
NPI 1467685982 · KALAMAZOO, MI. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$5,372 in 54 payments from 14 companies in 2025. Trend: 2023 $6,605 · 2024 $1,659 · 2025 $5,372
Consulting: $2,782Food & beverage: $2,039Travel & lodging: $551
| Company | Payments | Amount |
|---|---|---|
| GENZYME CORPORATION | 10 | $3,932 |
| TG Therapeutics, Inc. | 9 | $420 |
| EMD Serono, Inc. | 6 | $268 |
| Novartis Pharmaceuticals Corporation | 9 | $230 |
| ABBVIE INC. | 7 | $180 |
| MDD US Operations, LLC | 1 | $101 |
| Eisai Inc. | 2 | $49 |
| Celgene Corporation | 2 | $40 |
| ACADIA Pharmaceuticals Inc | 2 | $37 |
| PFIZER INC. | 2 | $30 |
Products named: BRIUMVI, KESIMPTA, Mavenclad, QULIPTA, Leqembi, ZEPOSIA, NUPLAZID, NURTEC ODT.
Industry payments across MI — which companies pay providers there.
